Edmonton Obesity Staging System (EOSS)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Stage 00–0
- Stage 11–1
- Stage 22–2
- Stage 33–3
The Edmonton Obesity Staging System (EOSS) calculates evaluating glycemic control, metabolic decompensation severity, and long-term endocrine risks. Key inputs include obesity risk factors. Scores guide titrating insulin infusion protocols, managing fluid-electrolyte resuscitation, and long-term risk reduction. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Stratifies the presence and severity of obesity-related health impairments across medical, functional, and psychological domains to guide treatment decisions and predict outcomes.
Clinical Indication
The Edmonton Obesity Staging System (EOSS) is indicated for bedside clinical practice to support Stratifies the presence and severity of obesity-related health impairments across medical, functional, and psychological domains to guide treatment decisions and predict outcomes.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with diabetes mellitus, diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, thyroid storm, or adrenal crisis. Clinical application is indicated across Endocrinology clinics, inpatient metabolic services, and acute diabetes care units.
Limitations & Contraindications
Severe hyperglycemia lowers measured serum sodium; corrected sodium equations must guide intravenous fluid selection.
Clinical Pearls & Action Plan
Serial monitoring of serum electrolytes, potassium kinetics, venous pH, and anion gap is mandatory during acute metabolic crisis management. Guideline pearl: The system can help guide treatment intensity and resource allocation for obesity management..
EOSS Stage = max(obesity_risk_factors, physical_symptoms, psychological_symptoms). The highest stage rating across all three domains determines the final EOSS stage.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| obesity_risk_factors | integer | Yes | Obesity-related medical risk factors and comorbidities(stage) |
| physical_symptoms | integer | Yes | Physical symptoms and functional limitations related to obesity(stage) |
| psychological_symptoms | integer | Yes | Psychological symptoms and mental health impact related to obesity(stage) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Stage 0 | No obesity-related health impairments |
| 1–1 | Stage 1 | Mild obesity-related health impairments |
| 2–2 | Stage 2 | Moderate obesity-related health impairments |
| 3–3 | Stage 3 | Severe obesity-related health impairments |
| 4–4 | Stage 4 | End-stage obesity-related health impairments |
Evidence-Based References (EBM)
- Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33(3):289-95. doi: 10.1038/ijo.2009.2.DOI: 10.1038/ijo.2009.2
- Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):E1059-66. doi: 10.1503/cmaj.110387.DOI: 10.1503/cmaj.110387
- Aasheim ET, Aylwin SJ, Radhakrishnan ST, Sood AS, Jovanovic Z, Olbers T, et al. Assessment of Obesity Beyond Body Mass Index to Guide Treatment. Curr Cardiol Rep. 2017;19(5):33. doi: 10.1007/s11886-017-0849-1.DOI: 10.1007/s11886-017-0849-1
- Canning KL, Brown RE, Jamnik VK, Salmon A, Ardern CI, Kuk JL. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. BMJ Open Diabetes Res Care. 2017;5(1):e000379. doi: 10.1136/bmjdrc-2016-000379.DOI: 10.1136/bmjdrc-2016-000379